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Pregnancy-Associated Plasma Protein-A
evels in Patients With Acute Coronary Syndromes
omparison With Markers of Systemic
nflammation, Platelet Activation, and Myocardial Necrosis
hristopher Heeschen, MD,* Stefanie Dimmeler, PHD,* Christian W. Hamm, MD, FACC,†
tephan Fichtlscherer, MD,* Maarten L. Simoons, MD, FACC,‡ Andreas M. Zeiher, MD, FACC,*
or the CAPTURE Study Investigators
rankfurt and Bad Nauheim, Germany; and Rotterdam, the Netherlands
OBJECTIVES The goal of this study was to determine the predictive value of pregnancy-associated plasma
protein-A (PAPP-A) in patients with acute coronary syndromes (ACS).
BACKGROUND Pregnancy-associated plasma protein-A is a zinc-binding matrix metalloproteinase abun-
dantly expressed in eroded and ruptured plaques and may serve as a marker of plaque
destabilization.
METHODS In 547 patients with angiographically validated ACS and in a heterogeneous emergency room
population of 644 patients with acute chest pain, respectively, PAPP-A as well as markers of
myocardial necrosis (troponin T [TnT]), ischemia (vascular endothelial growth factor
[VEGF]), inflammation (high-sensitivity C-reactive protein [hsCRP]), anti-inflammatory
activity (interleukin [IL]-10), and platelet activation (soluble CD40 ligand [sCD40L]) were
determined. Patients were followed for the occurrence of death or myocardial infarction.
RESULTS In patients with ACS, elevated PAPP-A levels (12.6 mIU/l) indicated an increased risk
(odds ratio 2.44 [95% confidence interval (CI) 1.43 to 4.15]; p  0.001). When the analysis
was restricted to TnT-negative patients, PAPP-A still identified a subgroup of high-risk
patients (odds ratio [OR] 2.72 [95% confidence interval (CI) 1.25 to 5.89]; p  0.009). In
a multivariable model, PAPP-A (OR 2.01; p  0.015), sCD40L (OR 2.37; p  0.003),
IL-10 (OR 0.43; p 0.003), and VEGF (OR 2.19; p 0.018) were independent predictors.
Prospective validation in patients with chest pain confirmed that PAPP-A levels reliably
identify high-risk patients (adjusted OR 2.32 [95% CI 1.32 to 4.26]; p  0.008). Patients
negative for all three markers (TnT, sCD40L, and PAPP-A) were at very low cardiac risk (30
days: 3.0% event rate; no death).
CONCLUSIONS The PAPP-A level as a marker of plaque instability is a strong independent predictor of
cardiovascular events in patients with ACS. Simultaneous determination of biomarkers with
distinct pathophysiological profiles appears to remarkably improve risk stratification in
patients with ACS. (J Am Coll Cardiol 2005;45:229–37) © 2005 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.060of Cardiology Foundation
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alevated levels of circulating cardiac troponin, a marker of
yocardial necrosis, are found in about one-third of the
atients with acute coronary syndromes (ACS) and are
ssociated with an increased short-term risk of death and
onfatal myocardial infarction (1–4). Although the absolute
hort-term risk in troponin-negative patients is significantly
ower as compared with troponin-positive patients, the large
umber of patients without troponin elevation remains
linically challenging with respect to risk assessment and
herapeutic management. Specifically, the six-month risk of
eath or nonfatal myocardial infarction in troponin-negative
atients was 8.4% in the c7E3 Anti Platelet Therapy in
nstable Refractory angina (CAPTURE) trial (5). There-
ore, the simultaneous measurement of several biomarkers
hat reflect distinct pathophysiologic processes may improve
From *Molecular Cardiology, Department of Internal Medicine III, University of
rankfurt, Frankfurt, Germany; †Kerckhoff Heart Center, Bad Nauheim, Germany;
nd ‡Erasmus University, Thoraxcentre, Rotterdam, the Netherlands. Trial partici-
ants have been published previously (see reference 17).w
Manuscript received July 9, 2004; revised manuscript received September 22, 2004,
ccepted September 27, 2004.isk stratification in patients without evidence for myocar-
ial necrosis (6).
Convincing evidence suggests that both inflammatory as
ell as thrombotic mechanisms are involved in the patho-
hysiology of patients with ACS (7). The availability of a
ensitive and specific early marker of plaque instability,
hose levels become elevated before or even in the absence
f myocardial necrosis, should improve diagnostic and
herapeutic decision-making. Pregnancy-associated plasma
rotein-A (PAPP-A) is a high-molecular-weight, zinc-
inding matrix metalloproteinase belonging to the metz-
ncin superfamily of metalloproteinases (8,9) and was orig-
nally identified in the plasma of pregnant women (10). It is
idely used for the screening of fetal trisomy in the first
rimester of gestation; PAPP-A was also found to be
bundantly expressed in eroded and ruptured plaques, re-
pectively, but is only minimally expressed in stable plaques
11). However, a very recent study indicates that, even in
atients with stable coronary heart disease, PAPP-A levels
re associated with angiographic plaque complexity (12) and
ere suggested to predict recurrence of symptoms in pa-
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PAPP-A in Acute Coronary Syndromes January 18, 2005:229–37ients with ACS (13). However, the precise role of circu-
ating PAPP-A plasma levels for predicting hard end points
ike death or myocardial infarction in patients with ACS
emains to be determined. Most importantly, whether
APP-A plasma levels indeed provide additive and inde-
endent prognostic information compared with recently
stablished biomarkers in patients with ACS is entirely
nknown. Therefore, we compared the prognostic signifi-
ance of PAPP-A plasma levels with markers of systemic
nflammation, platelet activation, ischemia, and myocardial
ecrosis in two distinct study populations, a high-risk
opulation with refractory ACS and a large heterogeneous
roup of patients with chest pain (6,14–16).
ETHODS
linical trial population of patients with ACS. The
APTURE trial included patients with recurrent chest pain
t rest associated with electrocardiographic changes during
reatment with intravenous heparin and glyceryl trinitrate
17). All patients underwent coronary angiography before
andomization, indicating significant coronary artery disease
ith a culprit lesion70% suitable for angioplasty. Heparin
as administered from before randomization until at least
h after the percutaneous coronary intervention. For all
atients, coronary angioplasty was scheduled between 18
nd 24 h after beginning study treatment. The patients were
andomly assigned to treatment with the glycoprotein IIb/
IIa receptor antagonist abciximab or placebo. Because
ther markers, such as troponin T (TnT) (5,18) and soluble
D40 ligand (sCD40L) (6), have been shown to interact
ith the treatment effect of abciximab, we separately ana-
yzed patients with available blood samples enrolled in the
lacebo arm (n 547; 86% of placebo patients) and patients
nrolled in the abciximab arm (n  547; 87% of abciximab
atients). For all patients, the first available blood sample
ollected after a mean time of 8.7  4.9 h after onset of
ymptoms was analyzed.
mergency room population of patients with acute chest
ain. A heterogeneous group of 626 consecutive patients
ith acute chest pain (161 females and 465 males, mean age
Abbreviations and Acronyms
ACS  acute coronary syndromes
CAPTURE c7E3  Anti Platelet Therapy in Unstable
Refractory Angina trial
CI  confidence interval
hsCRP  high-sensitivity C-reactive protein
IL  interleukin
PAPP-A  pregnancy-associated plasma
protein A
ROC  receiver operating characteristic
sCD40L  soluble CD40 ligand
TnT  troponin T
VEGF  vascular endothelial growth factor1 years [range 38 to 82 years]) presenting to the emergency eoom at the University of Hamburg with acute chest pain
asting less than 12 h. Patients with characteristic ST-
egment elevations were excluded. The presence of coronary
rtery disease was documented by one of the following
riteria: electrocardiographic evidence of myocardial isch-
mia (new ST-segment depression or T-wave inversion), a
istory of coronary heart disease (myocardial infarction or
oronary revascularization, a positive exercise stress test, or
arrowing of at least 50% of the luminal diameter of a major
oronary artery on a current angiogram). Patients without
oronary heart disease had to have a normal coronary
ngiogram. Blood samples were collected at the time of
rrival in the emergency room (5.1  3.4 h after onset of
ymptoms before initiation of treatment), and a second
lood sample was drawn 4 h later.
iochemical analysis. Determination of the cardiac mark-
rs was performed blinded to the patients’ histories and the
llocated treatment at the research laboratory of the Uni-
ersity of Frankfurt. High-sensitivity interleukin (IL), vas-
ular endothelial growth factor (VEGF), and sCD40L were
easured by ELISA (both R&D Systems, Wiesbaden,
ermany). We used the following, previously established
iagnostic threshold values: 5.0 g/l for sCD40L, 300 ng/l
or VEGF, and 3.5 ng/l for IL-10 (6,14,15). Cardiac TnT
nd PAPP-A were determined using a one-step enzyme
mmunoassay based on electrochemiluminescence technol-
gy (Elecsys 2010, Roche Diagnostics, Mannheim, Ger-
any). Using internal controls, total imprecision for
APP-A over the eight-week period was 8.5%. High-
ensitivity C-reactive protein (hsCRP) was measured using
he Behring BN II Nephelometer (Dade-Behring, Deer-
eld, Illinois). A diagnostic threshold value of 10 mg/l was
sed (16,19).
tatistical methods. A logistic regression model was used
o estimate the relative risk for cardiovascular events, and
atients were categorized in quintiles of PAPP-A levels
20). Primary end points were mortality and nonfatal
yocardial infarction after 30 days (chest pain study) and 6
onths (CAPTURE trial), respectively. For each time
oint (24 h, 72 h, 30 days, and 6 months), the logistic
egression model was used to estimate the relative risk for
eath and myocardial infarction. Post-hoc analysis of
APP-A quintiles was performed using the logistic regres-
ion model, with PAPP-A quintiles as a categorical variable,
nd the first quintile served as the reference group. Receiver
perating characteristics (ROC) curve analysis over the
ynamic range of the PAPP-A assay was used to identify
he threshold level for PAPP-A providing the highest
redictive value. Cumulative survival was univariately eval-
ated by Kaplan-Meier analysis (log-rank test). The effect
f baseline characteristics (with p  0.10 necessary to enter
variable into the model) and other biochemical markers on
ny observed associations between PAPP-A levels and
ardiovascular events was analyzed using stepwise logistic
egression models. All results for continuous variables are
xpressed as means SD. Continuous variables were tested
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January 18, 2005:229–37 PAPP-A in Acute Coronary Syndromesor normal distribution with the Kolmogorov-Smirnov test.
omparisons between groups were analyzed by t test (two-
ided) or by Mann-Whitney U test for not normally
istributed variables. Comparison of categorical variables
as generated by the Pearson chi-square test. Values of
 0.05 were considered statistically significant. All anal-
ses were performed with SPSS 11.5 (SPSS Inc., Chicago,
llinois).
ESULTS
aseline PAPP-A plasma levels showed a mean level of 14.2
IU/l (median 9.3 mIU/l; range 0.2 to 105.4 mIU/l).
hen PAPP-A plasma levels were linked to traditional risk
arkers, PAPP-A concentrations did not correlate with
nT levels (Spearman rank correlation coefficient r  0.11;
 0.16) and were similar in patients with high TnT
lasma levels and in patients with low TnT plasma levels
Fig. 1). Only for illustrative purposes, outliers are marked
s circles, whereas all data points were included in the
tatistical analysis. Similarly, VEGF (r  0.08; p  0.07)
nd IL-10 plasma levels (r0.04; p 0.35) did not show
ny association with PAPP-A plasma levels. In contrast,
ivariate correlation analysis revealed a significant correla-
ion between PAPP-A and hsCRP as well as between
APP-A and sCD40L, although the correlation coefficients
ere low with r 0.21 for hsCRP (p 0.001) and r 0.18
or sCD40L (p  0.001). However, if the analysis was
estricted to patients without myocardial necrosis (no tro-
onin elevation), the correlation between hsCRP and
APP-A became more obvious with an r value of 0.68 (p 
.001). Consequently, patients with elevated PAPP-A lev-
ls had significantly higher hsCRP and sCD40L levels,
espectively (Fig. 2).
nteraction between PAPP-A plasma levels and cardiac
isk. Patients were stratified into quintiles according to
heir measured PAPP-A levels: (PAPP-A_1) 4.5 mIU/l
n  111), (PAPP-A_2) 4.5 to 7.5 mIU/l (n  108),
PAPP-A_3) 7.6 to 12.6 mIU/l (n  109), (PAPP-A_4)
2.7 to 24.0 mIU/l (n  110), and (PAPP-A_5) 24.0
igure 1. Pregnancy-associated plasma protein A (PAPP-A) and high-
ensitivity C-reactive protein (hsCRP) plasma levels, respectively, accord-
ng to the baseline troponin T status. Only for illustrative purposes, outliers
re marked as circles. Importantly, all data points were included in the
tatistical analysis.IU/l (n  109), respectively. For the initial 24-h period,
s
0he combined end points of mortality and nonfatal myocar-
ial infarction did not differ between the quintiles (p 
.69) (Fig. 3). For the 72-h follow-up including peri-
nterventional events, the difference in cardiac events be-
ween the quintiles reached a level of statistical significance
p  0.019). During 30-day and 6-month follow-up, the
vent rate curves continued to diverge, resulting in highly
ignificant differences between the quintiles both at 30 days
p 0.008) and 6 months of follow-up (p 0.004). For the
-month follow-up data, post-hoc analysis of the PAPP-A
uintiles using a logistic regression model revealed that only
he upper two PAPP-A quintiles (4th quintile: p  0.034;
th quintile: p  0.002) significantly differed from the first
APP-A quintile, which served as a reference. Consistent
ith these results, ROC curve analysis verified a threshold
evel of 12.6 mIU/l PAPP-A for maximized predictive value
Fig. 4).
Therefore, the study population was dichotomized ac-
ording to the calculated threshold level of 12.6 mIU/l,
igure 2. Soluble CD40 ligand and high-sensitivity C-reactive protein
hsCRP) plasma levels, respectively, according to the baseline pregnancy-
ssociated plasma protein A (PAPP-A) status. Only for illustrative pur-
oses, outliers are marked as circles. Importantly, all data points were
ncluded in the statistical analysis.
igure 3. Association between the pregnancy-associated plasma protein A
PAPP-A) plasma levels and the cardiac event rate at 24 h, 72 h, 30 days,
nd 6 months according to the PAPP-A quintile in the placebo group of
he Anti Platelet Therapy in Unstable Refractory Angina (CAPTURE)
tudy (n  547). Differences in event rates between the quintiles were
ignificant at 72 h (p  0.019), 30 days (p  0.008), and 6 months (p 
.004) of follow-up. MI  myocardial infarction.
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PAPP-A in Acute Coronary Syndromes January 18, 2005:229–37esulting in 219 patients with elevated PAPP-A levels
40.0%). Besides higher levels of hsCRP and sCD40L,
espectively, in patients with elevated PAPP-A plasma
evels, baseline characteristics in patients with elevated
APP-A plasma levels were not significantly different from
atients with low PAPP-A plasma levels (Table 1). The
dds ratios for death and myocardial infarction (adjusted for
igure 4. Receiver operating characteristic curve analysis for the predictive
alue of pregnancy-associated plasma protein A (PAPP-A) plasma levels
or the occurrence of death or nonfatal myocardial infarction at six months
f follow-up (n  547). Solid line  sensitivity (%); dotted line 
pecificity (%).
able 1. Baseline Characteristics According to the PAPP-A
tatus
PAPP-A
Low
PAPP-A
High p Value
328 219
ale 70.2% 71.9% 0.62
ge (yrs) 60.5  11.0 62.2  10.4 0.39
roponin T 0.1 g/l 36.4% 39.2% 0.23
EGF 300 ng/l 50.8% 54.3% 0.43
RP 10 mg/l 37.3% 56.2% <0.001
L-10 3.5 ng/l 57.3% 53.4% 0.38
CD40L 5.0 g/l 33.4% 51.4% <0.001
T-segment depression 45.1% 53.6% 0.062
-wave inversion 51.7% 51.7% 1.00
istory of
Angina 4 weeks 55.5% 56.3% 0.64
Infarction 30 days 13.3% 12.5% 0.89
Infarction 30 days 20.3% 20.6% 0.90
PTCA 17.6% 17.4% 0.75
CABG 3.4% 3.5% 0.98
isk factors
Diabetes 9.5% 10.7% 0.97
Hypertension 34.6% 37.4% 0.64
Current smokers 40.9% 42.6% 0.41
edication
Aspirin 98.1% 97.8% 1.00
Heparin IV 99.0% 98.8% 1.00
Nitrates IV 99.5% 99.2% 1.00
Beta-blockers 63.5% 62.9% 0.94
old values indicate significant differences.
CABG  coronary artery bypass grafting; CRP  C-reactive protein; IL-10 
nterleukin-10; IV  intravenous; PAPP-A  pregnancy-associated plasma proteinb
; PTCA  percutaneous transluminal coronary angioplasty; SCD40L  soluble
D40 ligand; VEGF  vascular endothelial growth factor.ifferences in baseline characteristics) were 1.07 (95% con-
dence interval [CI] 0.34 to 3.42; p  0.91) at 24 h, 2.74
95% CI 1.44 to 5.22; p  0.002) at 72 h (Fig. 5a), 2.84
95% CI 1.55 to 5.22; p 0.001) at 30 days, and 2.44 (95%
I 1.43 to 4.15; p  0.001) at 6 months (Fig. 5b).
ix-month cumulative event rates in patients with low
APP-A levels were 7.9% versus 17.4% for patients with
igh PAPP-A levels. This difference in event rates was also
riven by a higher mortality in patients with elevated
APP-A plasma levels (3.2% vs. 1.2%; p  0.098). Con-
istently, urgent revascularization procedures including per-
utaneous coronary intervention and coronary artery bypass
rafting were significantly higher in patients with elevated
APP-A plasma levels (13.6% vs. 7.9%; p  0.012).
on-urgent revascularization procedures during six months
f follow-up showed a higher incidence in patients with
igh PAPP-A plasma levels as compared with patients with
ow PAPP-A plasma levels (34.4% vs. 19.7%; p  0.005).
ffect of abciximab treatment on the predictive value of
APP-A levels. All patients with available blood samples
reated with either placebo or abciximab were included in
his analysis (n  1,090; 86.2% of the entire study popula-
ion). The association between cardiovascular risk and
APP-A quartiles remained significant in the abciximab
roup (p  0.014), albeit on a lower level of statistical
ignificance as compared with the placebo group (p 
.001). Consistently, logistic regression analysis indicated a
igure 5. Kaplan-Meier event rate curves showing the cumulative inci-
ence of death or nonfatal myocardial infarction (MI) at 72 h (a) and 6
onths of follow-up (b) according to the baseline pregnancy-associated
lasma protein A (PAPP-A) plasma level (diagnostic threshold 12.6
IU/l; n  547).orderline significant interaction between the efficacy of
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January 18, 2005:229–37 PAPP-A in Acute Coronary Syndromesreatment with abciximab and PAPP-A values (p  0.025).
ubsequently, in a multivariable model including TnT,
CD40L, and PAPP-A, sCD40L (p 0.001) remained the
nly independent predictor of the effect of abciximab.
ultimarker considerations. The predictive value of
APP-A was also apparent in patients without evidence for
yocardial necrosis; TnT-negative patients (threshold level
.1 g/l) with elevated PAPP-A levels were at significantly
igher risk as compared with TnT-negative patients with
ow PAPP-A levels (adjusted odds ratio 2.72 [95% CI 1.25
o 5.89]; p  0.009) (Fig. 6a). The predictive value of
APP-A was also observed for a reduced threshold level of
.01 g/l for TnT (adjusted odds ratio 3.97 [95% CI 1.24
o 12.68]; p  0.016). Troponin-T-positive patients suf-
ered from increased cardiovascular risk, and this was
articularly true for patients who also had elevated PAPP-A
lasma levels (adjusted odds ratio 1.94 [95% CI 1.02 to
.09]; p  0.027).
Most notably, the predictive value of PAPP-A was
estricted to patients with reduced levels of the anti-
nflammatory cytokine IL-10 (Fig. 6b). Logistic regression
nalysis indicated a significant interaction between the
redictive value of PAPP-A values and IL-10 levels (p 
.002). If IL-10 levels were increased (3.5 ng/l), patients
ith PAPP levels above the calculated threshold value of
2.6 mIU/l were protected from an increased cardiac risk
odds ratio 1.13 [95% CI 0.44 to 2.90]; p 0.81). However,
or patients with IL-10 values below 3.5 ng/l, increased
APP-A levels were associated with a marked increase in
ardiovascular risk (odds ratio 3.61 [95% CI 1.84 to 7.10];
 0.001).
In a stepwise multivariable logistic regression analysis
ncluding biochemical markers as well as baseline character-
igure 6. Predictive value of pregnancy-associated plasma protein A
PAPP-A) for the incidence of death and nonfatal myocardial infarction
MI) at six months of follow-up was also apparent in patients without
roponin T (TnT) elevation (a) and was restricted to patients with low
evels of the anti-inflammatory cytokine interleukin (IL)-10 (b). Diagnos-
ic thresholds were 12.6 mIU/l for PAPP-A, 10 mg/l for high-sensitivity
-reactive protein, and 3.5 ng/l for IL-10 (n  547). *p  0.01 versus
APP-A low; **p  0.01 versus PAPP-A low.stics, none of the established risk factors that were signif-
Bcant predictors in a univariable model was an independent
redictor after the dichotomized biochemical markers TnT,
sCRP, and sCD40L were introduced into the model
Table 2). Therefore, the stepwise multivariable analysis was
estricted to biochemical markers. Troponin T (p  0.008)
nd PAPP-A (p 0.007) remained independent significant
redictors of the patients’ outcome, whereas hsCRP lost
ignificance after PAPP-A was introduced into the model
p 0.003 without PAPP-A; p 0.16 after introduction of
APP-A) (Table 3; step I). Pregnancy-associated plasma
rotein A remained a significant predictor of the patients’
utcome after the inclusion of the anti-inflammatory cyto-
ine IL-10 (Table 3; step II) (p 0.006) and after inclusion
f sCD40L as a marker of platelet activation (Table 3; step
II) (p  0.015). After the introduction of VEGF as a
arker of myocardial ischemia, TnT lost its predictive value
or the six-month outcome (Table 3; step IV) (p  0.24
fter the introduction of VEGF vs. p  0.16 before the
able 2. Multivariable Logistic Regression Model for Death
nd Nonfatal Myocardial Infarction During Six Months of
ollow-Up
Variables Odds Ratio 95% CI p Value
ender 0.91 0.68 to 1.39 0.16
ge 65 yrs 1.36 0.91 to 1.82 0.34
iabetes mellitus 1.22 0.83 to 1.49 0.61
ypercholesterolemia 0.90 0.68 to 1.13 0.59
ypertension 1.00 0.89 to 1.04 1.00
istory of CHD 0.86 0.65 to 1.19 0.72
T-segment depression 1.29 0.72 to 2.31 0.39
roponin T 0.1 g/l 2.23 1.25 to 3.98 0.007
RP 10.0 mg/l 2.03 1.11 to 3.59 0.018
APP-A 12.6 mIU/l 2.33 1.30 to 4.17 0.005
old values indicate significant differences.
CHD  coronary heart disease; CI  confidence interval; other abbreviations as
n Table 1.
able 3. Multimarker Assessment: Stepwise Multivariable
ogistic Regression Model for Death and Nonfatal Myocardial
nfarction During Six Months of Follow-Up
Step Variables in the Model Odds Ratio 95% CI p Value
CRP 10 mg/l 1.49 0.86 to 2.59 0.16
TnT 0.1 g/l 2.07 1.21 to 3.56 0.008
PAPP-A 12.6 mIU/l 2.13 1.24 to 3.68 0.007
I CRP 10 mg/l 1.44 0.67 to 2.17 0.50
TnT 0.1 g/l 2.13 1.24 to 3.69 0.006
PAPP-A 12.6 mIU/l 2.18 1.25 to 3.78 0.006
IL-10 3.5 ng/l 0.47 0.26 to 0.82 0.008
II CRP 10 mg/l 1.23 0.68 to 2.19 0.49
TnT 0.1 g/l 1.93 1.12 to 3.35 0.019
PAPP-A 12.6 mIU/l 2.05 1.18 to 3.32 0.015
IL-10 3.5 ng/l 0.42 0.24 to 0.74 0.002
sCD40L 5 g/l 2.45 1.39 to 4.32 0.002
V TnT 0.1 g/l 1.43 0.79 to 2.60 0.24
PAPP-A 12.6 mIU/l 2.01 1.14 to 3.49 0.014
IL-10 3.5 ng/l 0.43 0.25 to 0.76 0.003
sCD40L 5 g/l 2.37 1.34 to 4.18 0.003
VEGF 300 ng/l 2.19 1.14 to 4.18 0.018old values indicate significant differences.
TnT  troponin T; other abbreviations as in Tables 1 and 2.
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PAPP-A in Acute Coronary Syndromes January 18, 2005:229–37ntroduction of VEGF), whereas PAPP-A remained a
ignificant independent predictor (p  0.014).
rospective validation in emergency room patients with
cute chest pain. To investigate whether the predictive
alue of PAPP-A can be used for risk stratification of a
ore heterogeneous population of patients with acute chest
ain presenting to the emergency room, we prospectively
nrolled a total of 644 patients suspicious for having an
CS. When the first blood sample was drawn, none of the
hest pain patients had received anticoagulant treatment,
hich may have affected the inflammatory-thrombotic cas-
ade. Despite similar clinical presentation at the time of
rrival, patients were finally classified as follows: 323 pa-
ients with ACS, 105 patients with stable angina, 19
atients with congestive heart failure, and 197 patients with
o evidence of coronary heart disease.
Pregnancy-associated plasma protein A levels were sig-
ificantly higher in patients with ACS (mean 20.9 mIU/l;
edian 4.9 mIU/l [range 0.1 to 362.5 mIU/l]) as compared
ith patients with stable angina (mean 8.7 mIU/l; median
.9 mIU/l [range 0.1 to 113.9 mIU/l]; p  0.007) and
atients without evidence for coronary heart disease (mean
.2 mIU/l; median 1.4 mIU/l [range 0.1 to 54.1 mIU/l];
 0.001 vs. patients with ACS; p  0.044 vs. patients
ith stable angina), respectively. Mean PAPP-A levels in
atients with non–ST-segment elevation myocardial infarc-
ion did not significantly differ from mean PAPP-A levels in
atients with unstable angina (non–ST-segment elevation
yocardial infarction: mean 27.4 mIU/l; median 4.0 mIU/l
range 0.1 to 362.5 mIU/l]; unstable angina: mean 18.1
IU/l; median 5.3 mIU/l [range 0.1 to 221.1 mIU/l];
 0.50).
A total of 65 events (including 18 fatal events) were
ecorded during 30 days of follow-up. Using the prespeci-
ed threshold value for PAPP-A of 12.6 mIU/l, patients
ith high PAPP-A levels were at significantly increased risk
s compared with patients with low PAPP-A levels (event
ate 16.9% vs. 7.9%; univariate analysis: odds ratio, 2.38
95% CI 1.40 to 4.05]; p  0.001; multivariable analysis:
djusted odds ratio, 2.32 [95% CI 1.32 to 4.26]; p 0.008).
owever, maximized predictive value as derived from ROC
urve analysis was obtained at a threshold levels as low as 7.0
IU/l (event rate 18.4% vs. 6.6%; univariate analysis: odds
atio, 3.19 [95% CI 1.90 to 5.37]; p  0.001; multivariable
nalysis: adjusted odds ratio, 3.08 [95% CI 1.85 to 5.02;
 0.001). Pregnancy-associated plasma protein A was a
owerful predictor both in patients with low TnT levels and
n patients with high TnT levels (Fig. 7a). Using a multi-
arker approach, TnT (odds ratio 9.24 [95% CI 5.13 to
6.64]; p  0.001), sCD40L (odds ratio 2.93 [95% CI 1.65
o 5.22]; p  0.001), and PAPP-A (odds ratio 3.11 [95%
I 1.74 to 5.56]; p  0.001) emerged as independent
owerful predictors of cardiovascular events during 30 days
f follow-up. Patients who were negative for all three
arkers (TnT, sCD40L, and PAPP-A) were at very low iardiac risk (30 days of follow-up: no death; 3.0% rate for
onfatal myocardial infarction) (Fig. 7b).
ISCUSSION
he results of the present study demonstrate that elevated
lood levels of the metalloproteinase PAPP-A are associated
ith adverse outcome in patients with ACS. In line with a very
ecent study (13), the predictive value of PAPP-A plasma
evels was also prominent in patients without troponin eleva-
ion. Thus, an increased PAPP-A plasma level is not only a
arker of plaque instability favoring the development of ACS,
ut—more importantly—is indicative of a poor prognosis
efore the occurrence of an acute ischemic event caused by
laque instability. The finding that the predictive value of
APP-A was restricted to patients with low levels of the
nti-inflammatory cytokine IL-10 further supports the concept
hat the balance between pro- and anti-inflammatory cytokines
igure 7. Predictive value of pregnancy-associated plasma protein A
PAPP-A) in patients with acute chest pain for the incidence of death and
onfatal myocardial infarction (MI) during 30 days of follow-up (a). In
atients that were negative both for troponin T (TnT) and soluble CD40
igand (sCD40L), PAPP identified a subgroup suffering from increased
ardiovascular risk during 30 days of follow-up (b). Diagnostic thresholds
ere 12.6 mIU/l for PAPP-A, 0.1 g/l for TnT, and 5.0 g/l for sCD40L
n  644). Solid lines  TnT high; dotted lines  TnT low; open bars
PAPP-A low; solid bars  PAPP-A high.s a major determinant of patients’ outcome in ACS (15). By
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January 18, 2005:229–37 PAPP-A in Acute Coronary Syndromesultivariable regression analysis, several biochemical markers
ncluding TnT, sCD40L, IL-10, and PAPP-A were identified
s independent predictors of the patients’ outcome during the
ubsequent six months of follow-up.
Cardiac troponins are sensitive and specific markers of
yocardial necrosis secondary to thrombotic complications
uring an ACS and are highly predictive of the early clinical
ourse after the onset of ACS. However, risk stratification
n troponin-negative patients with ACS remains challeng-
ng. About two-thirds of the patients with ACS but no
T-segment elevations have normal troponin values, and
ore than half of the patients have inconclusive electrocar-
iographic findings (21). During the first weeks after the
nset of an ACS, the risk of death or nonfatal myocardial
nfarction in troponin-negative patients is about 5% to 8%
5,18). The present study demonstrates that PAPP-A levels
dentify a subgroup of patients without troponin elevation
ho are at substantially higher risk for cardiac events during
he early time course after onset of symptoms (30 days: OR
.33; 6 months: OR 2.72).
The progression and subsequent destabilization of ath-
rosclerotic plaques involves major change in the structure
f the arterial wall. The occurrence of a local inflammatory
tate in patients with ACS is well-established, as revealed by
nflammatory markers such as C-reactive protein (22–24).
etalloproteinases are also potential indicators of arterial
nflammation, and, by degrading extracellular matrix, may
ontribute to the fragility of the lipid-rich, atherosclerotic
laque and eventually to its rupture. As previously described
or several other metalloproteinases (MMP-1, -3, -12, or
13) (25,26), PAPP-A was only recently found to be
bundantly expressed in eroded and ruptured plaques,
hereas PAPP-A expression was undetectable in stable
laques (11). Other studies have also demonstrated that
atients with hyperechoic or isoechoic carotid plaques
xhibit significantly higher PAPP-A levels than those with
ypoechoic early carotid lesions (27). The exact role of
APP-A in the pathophysiology of ACS remains unclear;
APP-A has been shown to be a specific activator of
nsulin-like growth factor-I (9), a potent mediator of ath-
rosclerosis (28,29). As a matrix metalloproteinase,
APP-A may be involved in processing the plaques’ extra-
ellular matrix and, consequently, weakening the fibrous
ap. This may result in a plaque morphology that is more
usceptible to erosion, rupture, and subsequent thrombosis.
he present study demonstrates that a single PAPP-A
easurement provides significant predictive value for the
ncidence of death and nonfatal myocardial infarction in a
igh-risk population of patients with ACS as well as in a
eterogeneous group of patients presenting with acute chest
ain. These data suggest that PAPP-A plays an important
athophysiologic role in destabilization of the atheroscle-
otic plaque during ACS.
The production of PAPP-A by activated cells within the
therosclerotic lesion and its release into the extracellular
atrix appear to be strongly linked to the local inflamma- Hory process occurring within the arterial wall, as indicated
y the significant positive correlation observed between
RP and PAPP-A levels. Consistent with our previous data
n the important role of the inflammatory balance for the
rognosis of patients with coronary heart disease (15,30),
he predictive value of PAPP-A was almost entirely re-
tricted to patients with low levels of the anti-inflammatory
ytokine IL-10 (Fig. 6b). However, whereas CRP levels are
inked to troponin elevation (14), PAPP-A levels appear to
e less sensitive to minor myocardial injury, which might be
pecifically important in patients with ACS, of whom
pproximately one-third are positive for troponin at the
ime of arrival in the hospital (31). In addition, PAPP-A
evels neither interfered with nor compromise the predictive
ower of sCD40L, a marker of platelet activation. By
ultivariable analysis, PAPP-A, sCD40L, and TnT all
merged as independent predictors of adverse outcome
Table 2). Combining PAPP-A and sCD40L was especially
evealing in patients negative for TnT, suggesting that both
arkers reflect distinct pathways, which eventually contrib-
te to a proinflammatory and procoagulant milieu in the
oronary circulation. Supportive of a complementary rather
han a competing role to predict adverse outcome in patients
ith ACS are our findings that aggressive inhibition of
latelet aggregation by abciximab was specifically useful in
atients with elevated sCD40L levels (6).
Only recently we have identified placental growth factor
lasma levels as a powerful clinical biomarker of vascular
nflammation and adverse outcome in patients with ACS
32). Even though both placental growth factor and
APP-A are assumed to represent markers of vascular
nflammation, they are involved in distinct pathophysiologic
rocesses within atherosclerotic plaques. Therefore, it is not
urprising that they negatively influence the predictive value
f each other (data now shown). Whereas placental growth
actor was the stronger predictor in the CAPTURE cohort,
APP-A was the more powerful and independent predictor
n the chest pain cohort. Because we utilized an advanced
igh-sensitivity prototype assay for measurement of
APP-A that is suitable for routine use on an automatic
lectrochemiluminescent immunoassay system, whereas
lacental growth factor levels were determined with a
esearch ELISA system developed for quantification of
onsiderably higher levels of placental growth factor during
regnancy (33,34), it is not appropriate to directly compare
he PAPP-A results with the placental growth factor results,
nd future studies using an advanced placental growth factor
LISA system are required.
Potential limitations of the present study merit consider-
tion. First, because our blood samples were stored at 80°C
ntil analysis, we cannot exclude the possibility of protein
egradation. According to our experience, however, the delay
rom sampling to biochemical analysis in the core lab had no
ritical impact on the study results, and the plasma samples of
ur study were only thawed once for the present analysis.
owever, even if unaccounted for sources of protein instability
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PAPP-A in Acute Coronary Syndromes January 18, 2005:229–37ere present, their effects would minimally impact the validity
f the present results, because all samples were handled
dentically. Secondly, because of the retrospective nature of the
resent analysis of the CAPTURE study and the selection of
igh-risk patients with documented coronary heart disease,
esults from the CAPTURE trial may not be generalizable to
ore heterogeneous populations of patients with chest pain
resenting in the emergency room. We, therefore, prospec-
ively tested the prognostic value of PAPP-A in conjunction
ith other markers (TnT and soluble CD40L) in a “real-
orld” cohort of patients presenting with acute chest pain to
he emergency room. While we were able to confirm our
esults for the predictive value of PAPP-A in this validation set
f patients, additional studies are needed to understand how
arious markers including placental growth factor may com-
liment each other in risk stratification.
In summary, the results of the present study demonstrate
hat elevated levels of PAPP-A are associated with increased
ardiac risk. The predictive value of PAPP-A plasma levels
as independent of elevated troponin levels, which reflect
he acute risk secondary to thrombotic complications lead-
ng to myocardial injury during an ACS. Thus, an increased
APP-A level is not only a marker of plaque instability
avoring the progression to myocardial infarction, but is
ndicative of a poor prognosis even after the occurrence of an
cute ischemic event caused by plaque instability. Because
APP-A levels are relatively stable and no specific sampling
onditions are required for PAPP-A, this marker may
ndeed be suitable for routine clinical use, but further studies
re mandatory to truly identify the most reliable and
owerful marker of plaque instability. Although limitations
nherent to markers that are not specific to the coronary
rteries and/or myocardium remain, PAPP-A may repre-
ent an important tool for diagnostic and therapeutic
tratification of patients with ACS without evidence for
yocardial necrosis.
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